Draft:Julie Gralow
| Submission declined on 20 March 2024 by Shewasafairy (talk). This submission's references do not show that the subject qualifies for a Wikipedia article—that is, they do not show significant coverage (not just passing mentions) about the subject in published, reliable, secondary sources that are independent of the subject (see the guidelines on the notability of people). Before any resubmission, additional references meeting these criteria should be added (see technical help and learn about mistakes to avoid when addressing this issue). If no additional references exist, the subject is not suitable for Wikipedia.
Where to get help
How to improve a draft
You can also browse Wikipedia:Featured articles and Wikipedia:Good articles to find examples of Wikipedia's best writing on topics similar to your proposed article. Improving your odds of a speedy review To improve your odds of a faster review, tag your draft with relevant WikiProject tags using the button below. This will let reviewers know a new draft has been submitted in their area of interest. For instance, if you wrote about a female astronomer, you would want to add the Biography, Astronomy, and Women scientists tags. Editor resources
|  |
Julie Gralow MD, FACP, FASCO | |
|---|---|
| Occupation | Chief Medical Officer of the American Society of Clinical Oncology |
| Medical career | |
| Profession | Medical Oncologist |
| Field | Breast Cancer, Global Oncology, Survivorship |
| Awards | ASCO Career Development Award (1995-1998)
American Society of Clinical Oncology (FASCO), 2008 ASCO Humanitarian Award, 2018 |
Julie Gralow, Chief Medical Officer and Executive Vice President of the American Society of Clinical Oncology (ASCO), professor of medical oncology and director of breast medical oncology at the University of Washington, Fred Hutchinson Cancer Research Center, and the Seattle Cancer Care AllianceDr. Gralow’s specialty and research focus is breast cancer, and advocacy on a global scale.
Education[edit]
Julie Gralow received her bachelor's degree from Stanford University and her medical degree from the University of Southern California School of Medicine. She completed her training in internal medicine at Brigham and Women’s Hospital at Harvard Medical School and a medical oncology fellowship at the University of Washington/Fred Hutchinson Cancer Research Center..[1].
Career[edit]
Early in her career, Dr. Gralow was influenced by mentors such as Richard Miller, MD, and Ron Levy, MD, leading to her involvement in oncology research. Her work during fellowship focused on the clinical relevance of HER2 in breast cancer, contributing to the development of HER2-targeted therapies.
As a junior faculty member, Dr. Gralow participated in and led several clinical trials within the SWOG Cancer Research Network, advancing the treatment of breast cancer. Her leadership roles in SWOG included Vice Chair of the Breast Cancer Committee and Executive Officer of Breast and Lung Cancer.
- SWOG Research Principal Investigator (PI) roles:
- S0102 Phase II (anti-tubulins in metastatic breast cancer)
- S0307 Phase III (bisphosphonates in early stage breast cancer)
- S0316 (elderly enrollment)
- Senior PI roles:
- S0702 (ONJ Registry)
- S1007 Phase III (21-gene Recurrence Score in LN+)
- S1416 (cisplatin +/- veliparib in BRCA+)
- SWOG Leadership roles:
- Vice-Chair, Breast Cancer Committee (2000-2013)
- Executive Officer, Breast and Lung Cancer (2013-2021)
[edit]
- Committee Membership:
- Member, ASCO Public Issues Committee (1999-2004); Co-Chair (2000-2002)
- Member, ASCO Health Services Research Committee (2000-2004)
- Member, ASCO Program Committee (2000)
- Member, ASCO Communications Committee (2005-2009), Chair (2007/2008)
- Chair, ASCO Patient Communication Subcommittee (2005-2007)
- Member, ASCO Nominating Committee (elected position) (2008-2011)
- Member, ASCO International Affairs Committee (2013-2016)
- Member, ASCO Education Committee, Global Health Track (2016-2018)
- Member, Special Awards Committee (2018-2021)
Guidelines[edit]
- ASCO Bisphosphonates in breast cancer guideline 2001-2003
- ASCO Aromatase inhibitors as adjuvant therapy guideline 2002-2004
- ASCO Breast Cancer Guideline Advisory Group 2014-2018
- ASCO Chemo and targeted therapy for advanced HER2-negative breast cancer guideline
- ASCO Osteonecrosis of the Jaw Consensus panel 2018-2021
- ASCO Chemo and targeted therapy for advanced her2+ breast cancer guideline, 2019-2021
- Co-Chair, ASCO Resource Stratified Guideline Advisory Group 2016-2021
Mentorship[edit]
- Mentor, ASCO International Development and Education Award (IDEA) 2010, 2014, 2015, 2018
- Mentor, ASCO Global Oncology YIA award, 2019
- Mentor, ASCO Women’s Networking Lounge, AM 2018, 2019, 2022
Editorial Boards[edit]
- Editor, Breast Cancer, ASCO Cancer.Net 2009-2012
- Editor, ASCO SEP Breast chapter 2018-2020
- Editorial Board, ASCO/ESMO Global Curriculum in Medical Oncology 2020-2021
Task Forces and Panels[edit]
- Member, ASCO-CAP Panel on Enhancing Pathology in Developing Countries 2015-2016
- Member, ASCO Global Oncology Leadership Task Force 2014-2016
- Chair, ASCO Academic Global Oncology Task Force 2017-2019
Awards[edit]
- ASCO Career Development Award (1995-1998)
- American Society of Clinical Oncology (FASCO) (Statesman Award), 2008
- ASCO Humanitarian Award, 2018, acknowledging significant efforts in improving cancer care and advocating for cancer patients globally, especially in low- and middle-resource countries.
Advocacy and Global Health Initiatives[edit]
In 1995, Dr. Gralow founded Team Survivor Northwest, promoting exercise and fitness among women cancer survivors. Her commitment to global health was further demonstrated through the establishment of the Women’s Empowerment Cancer Advocacy Network (WE CAN) in 2003, focusing on improving cancer outcomes through education and advocacy in low- and middle-income countries[2]
- Led the Ukraine Breast Cancer Assistance Project (1997-2000), focusing on chemotherapy trials and psychosocial support.
- Founded the Women’s Empowerment Cancer Advocacy Network (WE CAN) in 2003 to empower and educate breast and cervical cancer patient advocates globally.
- Contributed to the expansion of WE CAN[3] in Eastern Europe, Central Asia, and East/Southern Africa, holding summits and workshops in various countries to improve cancer care and advocacy.
Dr. Gralow's partnership with the Fred Hutchinson Cancer Research Center and the Uganda Cancer Institute exemplifies her efforts to enhance cancer care in Uganda through clinical care, training, and research[4]
References[edit]
- ^ "Julie Gralow, MD". www.patientpower.info. Retrieved 2024-03-18.
- ^ "ASCO Announces Dr. Julie R. Gralow as New Chief Medical Officer". ASCO Connection. 2020-11-20. Retrieved 2024-03-18.
- ^ "Dr Julie Gralow, on the gender gap in health care leadership and effective ways to support leadership roles for women – City Cancer Challenge". citycancerchallenge.org. 2022-10-17. Retrieved 2024-03-18.
- ^ "Closing the Divide Between Survivorship and Palliative Care: A Conversation With Dr. Julie Gralow". ASCO Connection. 2022-11-01. Retrieved 2024-03-18.